IBS C News and Research

RSS

Painkillers may not offer relief to people suffering from irritable bowel syndrome

University of Adelaide researchers have discovered that the immune system is defective in people suffering from irritable bowel syndrome, which is a major reason why sufferers have ongoing issues with pain.

21 Aug 2014

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

13 Aug 2014

Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning the role of immune-system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).

18 Jul 2014

Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS).

18 Jul 2014

Independent testing organization confirms VSL#3 formulation as probiotic product

Probiotics have gained in popularity in recent years and consumers now have many to choose from. However, only 14 of 19 successfully tested through Consumer Lab's quality certification program probiotics.

9 Jul 2014

New technology in field of optogenetics can remotely control specific receptors by light

Institute for Basic Science (IBS), the main organization of the International Science and Business Belt project in South Korea, has announced that a group of researchers, led by professor Won Do Heo, have developed a new technology in the field of optogenetics that can remotely control specific receptors by light.

8 Jul 2014

Treating ulcerative colitis and Crohn’s disease

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract.

7 Jul 2014

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

2 Jul 2014

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines are generally being defined as medicines which are non-mainstream medicines and are mostly given together with conventional medicines.

23 Jun 2014

New technology to control specific protein functions in living cells by using lights

Researchers at the Institute for Basic Science (IBS) in South Korea have succeeded in developing the world's first technology to control specific protein functions in living cells by using lights, which may be useful in future cancer cell research.

18 Jun 2014

Squatty Potty toilet stool improves severity of constipation symptoms

When used as a treatment, the original Squatty Potty (www.squattypotty.com) toilet stool significantly improves the severity of constipation symptoms within one month of use among 84 percent of the participants of a recently released scientific study.

4 Jun 2014

Salix Pharmaceuticals' total net product revenue increases 90% to $384.4 million in Q1 2014

Salix Pharmaceuticals, Ltd. today announced financial and operating results for the first quarter ended March 31, 2014, and other business updates.

9 May 2014

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW).

5 May 2014

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).

30 Apr 2014

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval.

28 Apr 2014

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

In the United States, approximately 179 million cases of acute diarrhea occur each year, and most of those cases are entirely preventable, a researcher from The University of Texas Health Science Center at Houston concluded in a New England Journal of Medicine review article.

23 Apr 2014

Prevalence of celiac disease on the rise among children with irritable bowel syndrome

There appears to be an increased prevalence of celiac disease among children with irritable bowel syndrome (IBS).

22 Apr 2014

Sanofi Korea launches gut health product, Probi Digestis

Probi has signed a distribution and supply agreement with Sanofi. Following this the Consumer Healthcare division of Sanofi Korea is making a major launch of Probi´s gut health product, Probi Digestis starting in April 2014. Probi has already delivered products and received substantial orders for the coming quarters.

15 Apr 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

Researchers identify genetic defect that causes a subset of irritable bowel syndrome

Is irritable bowel syndrome (IBS) caused by genetics, diet, past trauma, anxiety? All are thought to play a role, but now, for the first time, researchers have reported a defined genetic defect that causes a subset of IBS. The research was published in the journal Gastroenterology.

21 Mar 2014